60 related articles for article (PubMed ID: 1346346)
1. The importance of targeting the CD4+ T cell subset at the time of antigenic challenge for induction of prolonged vascularized allograft survival.
Sablinski T; Sayegh MH; Kut JP; Tilney NL; Milford EL; Kupiec-Weglinski JW
Transplantation; 1992 Jan; 53(1):219-21. PubMed ID: 1346346
[No Abstract] [Full Text] [Related]
2. Microchimerism and graft acceptance: cardiac allograft acceptance following antiadhesion molecules antibody therapy.
Hara MH; Tanigawa M; Matsuzaki M; Onitsuka T; Shibata K; Koga Y; Suzuki H; Yamashita A; Miyamoto M; Li XK; Suzuki S; Amemiya H; Yokoi Y; Iwaya M; Yamaguchi A; Masaki Y; Miyasaka M; Kimura H
Transplant Proc; 1996 Jun; 28(3):1370-1. PubMed ID: 8658699
[No Abstract] [Full Text] [Related]
3. Effect of recipient T cell subset depletion on graft coronary arteriosclerosis induction in the rat retransplant model.
Izutani H; Miyagawa S; Shirakura R; Mikata S; Tanemura M; Fukushima N; Nakata S; Matsuda H
Transplant Proc; 1996 Jun; 28(3):1828-9. PubMed ID: 8658903
[No Abstract] [Full Text] [Related]
4. Microchimerism and graft acceptance: IV. Cardiac allograft acceptance following anti-adhesion molecule antibody therapy.
Suzuki H; Hara MH; Miyahara T; Tanigawa M; Matsuzaki Y; Onitsuka T; Shibata K; Koga Y; Yamashita A; Miyamoto M; Suzuki S; Amemiya H; Iwaya M; Miyasaka M; Kimura H
Transplant Proc; 1996 Aug; 28(4):2058-60. PubMed ID: 8769155
[No Abstract] [Full Text] [Related]
5. Induction of transplantation tolerance using a nondepleting anti-CD4 MAb and donor-specific transfusion before transplantation: evidence that a critical period of time is required for the development of immunological unresponsiveness.
Saitovitch D; Bushell AR; Morris PJ; Wood KJ
Transplant Proc; 1995 Feb; 27(1):117-8. PubMed ID: 7878834
[No Abstract] [Full Text] [Related]
6. A short course of cyclosporin A combined with anti-CD4 and/or anti-TCR MAb treatment induces long-term acceptance of kidney allografts in the rat.
Lácha J; Chadimová M; Havlícková J; Brock J; Matl I; Volk HD; Lehmann M
Transplant Proc; 1995 Feb; 27(1):125-6. PubMed ID: 7878869
[No Abstract] [Full Text] [Related]
7. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease cytokine production.
Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
Transplant Proc; 1993 Feb; 25(1 Pt 1):823-4. PubMed ID: 8094913
[No Abstract] [Full Text] [Related]
8. In vivo immunosuppressive effects of monoclonal antibodies specific for CD3+, CD4+, CD8+, and MHC class II positive cells.
Stevens HP; Roche N; Hovius SE; Jonker M
Transplant Proc; 1990 Aug; 22(4):1783-4. PubMed ID: 2143861
[No Abstract] [Full Text] [Related]
9. Effect of anti-CD4 monoclonal antibody therapy on rat small bowel allograft survival.
Bowles MJ; Webster GA; Wood RF; Pockley AG
Transplant Proc; 1994 Jun; 26(3):1605. PubMed ID: 7913268
[No Abstract] [Full Text] [Related]
10. Anti-CD4 therapy induces a donor-specific, organ-nonspecific tolerance in allogeneic kidney graft recipients.
Kuttler B; Lehmann M; Lacha J; Brock J; Hahn HJ
Transplant Proc; 1994 Apr; 26(2):728-9. PubMed ID: 8171628
[No Abstract] [Full Text] [Related]
11. Prolongation of kidney and skin allograft survival in the rat by monoclonal antibody therapy directed to the RT6.1 T-cell alloantigen.
Fangmann J; Schwinzer R; Vogt P; Wonigeit K
Transplant Proc; 1991 Feb; 23(1 Pt 1):504-6. PubMed ID: 1990601
[No Abstract] [Full Text] [Related]
12. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
Woods M; Guy R; Waldmann H; Glennie M; Alexander DR
Cell Immunol; 1998 May; 185(2):101-13. PubMed ID: 9636688
[TBL] [Abstract][Full Text] [Related]
13. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
Hirsch R; Bluestone JA; Bare CV; Gress RE
Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
[No Abstract] [Full Text] [Related]
14. CD4 MAb therapy diminishes sensitization to xenoantigen and abrogates hyperacute rejection of hamster cardiac grafts in rats.
Sablinski T; Hancock WW; Schmidbauer G; Milford EL; Kupiec-Weglinski JW
Transplant Proc; 1992 Apr; 24(2):528-30. PubMed ID: 1566417
[No Abstract] [Full Text] [Related]
15. Therapeutic strategies targeted at CD4+ cells obviate accelerated rejection of cardiac allografts in sensitized rats.
Sablinski T; Sayegh MH; Kut JP; Hancock WW; Milford EL; Tilney NL; Kupiec-Weglinski JW
Transplant Proc; 1991 Feb; 23(1 Pt 1):268-9. PubMed ID: 1990530
[No Abstract] [Full Text] [Related]
16. Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mice.
Han WR; Zhan Y; Murray-Segal LJ; Brady JL; Lew AM; Mottram PL
Transplantation; 2000 Jul; 70(1):168-74. PubMed ID: 10919596
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of anti-CD4-induced T helper cell depletion and inhibition of function. Activation of T cells by the CD3 pathway inhibits anti-CD4-mediated T cell elimination and down-regulation of cell surface CD4.
Jamali I; Field EH; Fleming A; Cowdery JS
J Immunol; 1992 Mar; 148(6):1613-9. PubMed ID: 1347302
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the immunoregulatory capacity of anti-alpha/beta-TCR and anti-CD3 monoclonal antibodies.
Kurrle R; Schorlemmer HU; Shearman C; Lauffer L; Frank K; Kanzy EJ; Seiler FR
Transplant Proc; 1991 Feb; 23(1 Pt 1):272-6. PubMed ID: 1824982
[No Abstract] [Full Text] [Related]
19. Selective T-cell depletion of recipients in allogeneic small bowel transplantation (SBT) in the rat.
Deaton DH; Posselt AM; Naji A; Barker CF
Transplant Proc; 1991 Feb; 23(1 Pt 1):283-4. PubMed ID: 1899305
[No Abstract] [Full Text] [Related]
20. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Ellenhorn JD; Schreiber H; Bluestone JA
J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
